Is your QC Lab documenting the re-injection of samples?

A company recently received this 483 observation: 

…..Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards and test procedures designed to assure that components, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, there is no documentation or justification if GC and/or HPLC runs are repeated or aborted. For example, your firm performed a re-injection of ….. drug product sample, Lot ….., without documentation or explanation.

For more details on this observation as well as other observations pertaining to Laboratory Controls see  Issue 1019 available today.  It features observations pertaining to Active Pharmaceutical Ingredient (API) Manufacturing on our rotating page 3 topic as well as Medical Device Manufacturing Controls and Manufacturing Controls.

Stay in Compliance! Subscribe today!

Become A Subscriber And Stay Ahead of the FDA

To get the most out of GMP Trends®, sign up to one of our subscription packages for valuable, up-to-date information you won't find anywhere else! Every subscription provides the most frequently cited FDA 483 observations taken from recent FDA Inspections. The non-essential information is redacted to streamline the facts in an easily readable format. Join the thousands of professionals who rely on GMP Trends® to keep them informed of the latest FDA Enforcement Trends!

SUBSCRIBE NOW